Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
MCRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.53 - $26.42
Previous CloseN/A
Volume457.00K
Average Volume (3M)128.75K
Market Cap
$169.40M
Enterprise Value$139.20M
Total Cash (Recent Filing)$45.38M
Total Debt (Recent Filing)$87.43M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 18, 2025EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding8,754,570
10 Day Avg. Volume134,002
30 Day Avg. Volume128,746
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue23.36
Enterprise Value/Gross Profit-46.23
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$14.00Price Target Upside-26.28% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSeres has received a $50M installment fee and is set to receive another $23.5M, extending its cash runway into 1Q26.
Product DevelopmentSER-155 demonstrated initial signs of efficacy with a 77% relative risk reduction in bloodstream infections, as well as benefit on other measures vs. placebo.
Regulatory ProgressSER-155 has breakthrough designation, which should speed discussion with FDA.
Bears Say
Management ChangesLong-time CEO Eric Shaff would depart the company, with CLO Thomas DesRosier and CFO Marella Thorell appointed as co-CEOs.
Partnership And Funding ChallengesMCRB requires additional capital to support the study and stated that partnership discussions are advancing.
Study Design UncertaintyUncertainty around SER-155 study design and partnership discussion led to a lower probability of success from 35% to 20% and an increased discount rate from 6% to 34%.
Seres Therapeutics News
MCRB FAQ
What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $6.53 and its highest was $26.42 in the past 12 months.
What is Seres Therapeutics’s market cap?
Seres Therapeutics’s market cap is $169.40M.
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 81 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Aug 06, 2025. The company reported -$2.27 earnings per share for the quarter, beating the consensus estimate of -$2.49 by $0.22.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Overvalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is 0.44.
How many shares outstanding does Seres Therapeutics have?
Seres Therapeutics has 8,754,570 shares outstanding.
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of -$2.27 in its last earnings report, beating expectations of -$2.49. Following the earnings report the stock price went down -3.501%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Currently, no hedge funds are holding shares in MCRB
Seres Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (-26.28% Downside)
$14.00 (-26.28% Downside)
Blogger Sentiment
Bullish
MCRB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 163.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.73%
12-Months-Change
Fundamentals
Return on Equity
-3758.21%
Trailing 12-Months
Asset Growth
-55.30%
Trailing 12-Months
Company Description
Seres Therapeutics
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
MCRB Company Deck
MCRB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a generally optimistic outlook with significant progress in key areas such as the development of SER-155, financial management improvements, and strategic partnerships. However, the call also highlighted challenges related to the biotech environment and cash runway limitations, indicating a need for securing additional capital.View all MCRB earnings summariesMCRB Stock 12 Month Forecast
Average Price Target
$14.00
▼(-26.28% Downside)
Technical Analysis
Jasper Therapeutics
―
Elicio Therapeutics
―
Vor Biopharma
―
Instil Bio
―
Senti Biosciences
―
Ownership Overview
3.32% Insiders
4.98% Mutual Funds
13.70% Other Institutional Investors
74.16% Public Companies and
Individual Investors